Harmful bacteria in the gut microbiome damage the intestinal lining, trigger inflammation that can spread throughout the body, compete with beneficial microbes for resources, and produce metabolites linked to heart disease, insulin resistance, and mood disorders. Some of these bacteria are outside invaders, while others are residents that normally live in your gut peacefully but cause problems when they multiply unchecked.
Pathogens vs. Pathobionts
Not all harmful gut bacteria work the same way. There are two distinct categories worth understanding. True pathogens, like Salmonella and Shigella, are invaders from outside your body that cause acute illness. Pathobionts, on the other hand, are species that already live in your gut in small numbers and only become a problem when conditions shift in their favor. C. difficile is a classic example: it can coexist quietly with your other gut microbes, but after a round of antibiotics wipes out its competition, it multiplies rapidly and causes severe diarrhea and colitis.
A healthy, diverse microbiome keeps both types in check through what researchers call colonization resistance. Your beneficial bacteria suppress incoming pathogens and prevent resident pathobionts from overgrowing by competing for the same nutrients and space. When that community gets disrupted, whether by antibiotics, illness, poor diet, or other environmental factors, the door opens for harmful species to take over.
How They Break Down the Gut Lining
Your intestinal wall is a single layer of cells held together by tight junctions, protein structures that act like seals between cells. This barrier is supposed to let nutrients through while keeping bacteria and their byproducts contained within the gut. Harmful bacteria attack this system directly.
When pathogenic bacteria gain a foothold, they trigger intestinal inflammation that destroys the tight junctions between cells and damages the mucosal barrier. Once that barrier is compromised, bacteria and their toxic components leak through into the bloodstream. One of the most significant of these components is lipopolysaccharide (LPS), a molecule found in the outer membrane of gram-negative bacteria. LPS translocation into the blood activates an immune receptor called TLR4, which sets off a cascade of inflammatory signals throughout the body. This process, called metabolic endotoxemia, is essentially a low-grade infection state that can persist for months or years.
The damage is also self-reinforcing. Inflammation weakens the gut lining, which lets more bacterial products leak through, which triggers more inflammation. Breaking this cycle is one of the central challenges in treating gut-related conditions.
Competing With Beneficial Bacteria
Gut bacteria, both helpful and harmful, compete for the same pool of resources. In the large intestine, microbes break down undigested fibers like resistant starch, cellulose, inulin, and pectin, using them as carbon sources to fuel their growth. They also compete for nitrogen, iron, and zinc. When harmful species gain a competitive edge, they can crowd out the beneficial bacteria that produce protective compounds.
This matters because many of the gut’s health benefits come from what beneficial bacteria make as they digest fiber. Short-chain fatty acids (SCFAs), for instance, are produced by beneficial species and help maintain the gut lining, regulate immune function, and support healthy blood sugar levels. When harmful bacteria displace SCFA-producing species, intestinal permeability increases, more bacterial toxins leak into the bloodstream, and the metabolic consequences ripple outward.
Driving Insulin Resistance and Metabolic Problems
The connection between gut dysbiosis and metabolic disease runs through several overlapping pathways. The most direct involves LPS. When dysbiosis increases the population of gram-negative bacteria, LPS production rises. That LPS crosses the weakened gut barrier, enters the bloodstream, and activates inflammatory signaling that directly interferes with how your cells respond to insulin. Specifically, the inflammatory cascade blocks a key protein in the insulin signaling chain, shifting your metabolism toward insulin resistance.
Dysbiosis also alters the production of bile acids, amino acid derivatives, and other metabolites that influence glucose regulation. The loss of SCFA-producing bacteria compounds the problem, since SCFAs normally help maintain the gut barrier and regulate blood sugar. The result is a metabolic environment that favors weight gain, elevated blood sugar, and chronic low-grade inflammation, all hallmarks of metabolic syndrome.
Effects on Heart Health
One of the more striking discoveries in microbiome research is the link between gut bacteria and cardiovascular risk, driven largely by a metabolite called TMAO (trimethylamine N-oxide). Certain gut bacteria convert dietary compounds found in red meat, eggs, and other animal products into trimethylamine, which the liver then converts to TMAO.
Both animal and human studies have established a connection between elevated TMAO and cardiovascular disease, with animal models showing a causal relationship: administering TMAO increases cardiovascular risk, and eliminating it reduces risk. In a study of over 4,000 patients tracked for three years, those with the highest fasting TMAO levels had a significantly greater risk of major cardiovascular events compared to those with the lowest levels, with a clear graded relationship between rising TMAO and increasing risk. Among heart failure patients, mortality over a two-year follow-up was 46.6% in the high-TMAO group compared to 27.4% in the low-TMAO group.
Influence on the Brain and Mood
Your gut and brain communicate through a bidirectional pathway involving nerves, immune signals, and bacterial metabolites. Harmful shifts in gut bacteria are correlated with depression, Alzheimer’s disease, and attention-deficit/hyperactivity disorder, though researchers are still working out exactly how much is cause versus effect.
Some gut bacteria produce neurotransmitters like serotonin and GABA, but these molecules can’t cross the blood-brain barrier directly. Instead, they act on nerve endings in the gut wall, influencing brain function indirectly through the enteric nervous system. Other bacterial products take a more direct route: amino acids like tryptophan and tyrosine enter the bloodstream, cross into the brain, and serve as raw materials for neurotransmitter production. When dysbiosis alters the balance of these amino acids, it can shift neurotransmitter levels in the brain.
TMAO also appears to play a role here, serving as a potential risk factor in neurological disorders. In mouse models, TMAO worsened the outcomes of stroke. Another metabolite called p-cresol, produced when certain bacteria break down the amino acid tyrosine, has been linked to autism spectrum disorder, though the exact mechanism at the cellular level remains unclear.
What Dysbiosis Feels Like
Gut dysbiosis doesn’t always announce itself with dramatic symptoms. The most common signs are digestive: bloating, gas, diarrhea, constipation, or a noticeable change in your bowel habits. But because the effects of harmful bacteria extend well beyond the gut, you may also experience chronic fatigue, mood changes, or unexplained weight shifts. If intestinal symptoms develop alongside these broader changes, they may share the same root cause.
One marker doctors use to measure gut inflammation is fecal calprotectin, a protein released by immune cells in the intestinal lining. Levels below 50 micrograms per gram are considered normal, 50 to 100 is a moderate range that may warrant monitoring, and anything above 100 suggests significant intestinal inflammation. Higher calprotectin levels are associated with both microbial dysbiosis and changes in blood markers of systemic inflammation, reinforcing the idea that what happens in the gut doesn’t stay in the gut.